AMD Surges 6.7% on AI Deal 04/03/26
/
RSS Feed
AMD Surges 6.7% on AI Deal 04/03/26
Key Stories:
- Breaking news from Washington could introduce significant headwinds for big pharma. Policymakers are reportedly considering tariffs of up to 100% on certain branded and patented drugs, a move specifically targeting companies not agreeing to domestic price concessions. This proposal casts a long shadow over major international drugmakers like AbbVie, trading as NYSE:ABBV, whose substantial US business could face material pressure if these tariffs come to fruition. Investors should track legislative developments closely, as this could directly impact AbbVie’s revenue streams and growth narrative. Read more
- And the market’s reaction to those potential drug tariffs was swift and stark. We saw shares across the healthcare sector take a hit this afternoon, notably for AMN Healthcare Services, kidney care provider DaVita, pharmaceutical giant Bristol-Myers Squibb, vaccine developer Novavax, and yes, AbbVie again. Reports of these proposed 100% tariffs on imported branded drugs triggered broad selling pressure, indicating the market is taking this policy risk very seriously. The interconnectedness of the healthcare supply chain means even companies beyond direct drug manufacturers felt the ripple effect today. Read more
- Now, for a brighter note in the tech sector, Advanced Micro Devices, or AMD, the chip design powerhouse, saw its shares surge by a healthy 6.7% today. This positive momentum comes on the heels of a new partnership with CIQ, targeting open and power-efficient AI infrastructure. The collaboration aims to deliver AMD-optimized Rocky Linux and integrated software stacks, specifically designed for AI and high-performance computing workloads running on AMD’s data center solutions, including their Instinct GPUs and ROCm platform. This move firmly positions AMD at the core of next-generation AI, offering a robust alternative for investors looking at the AI chip space. Read more
- And diving deeper into Advanced Micro Devices, it’s clear the investment narrative around this company is shifting, with analysts actively revisiting their price targets. While some are maintaining an anchor fair value estimate around US$289.61, the underlying assumptions are being tweaked. Much of this reassessment revolves around AMD’s expanding GPU agreement with tech giant Meta, its strategic links to OpenAI, and a growing ecosystem in data center and edge inference. Investors will want to closely track how these pivotal AI deals and evolving ecosystem play out, as they are crucial to AMD’s long-term valuation. Read more
- Finally, let’s turn to the financial derivatives space, where CME Group, the Chicago-based exchange operator, is back in the spotlight. The company recently reported record trading volumes across every major product category, signaling robust activity in the derivatives markets. In a forward-looking move, CME Group is also forging new digital settlement partnerships, working with BMO and Google Cloud to enable 24/7 tokenized cash settlement, while expanding data access through Stocktwits. While its shares saw a modest 1-day return of 2.75% and a 7-day return of 2.53%, it’s worth noting the stock experienced a 30-day return of negative 6.16%, indicating some recent volatility. These innovations in digital settlement could be a key growth driver for CME going forward, making it one to watch. Read more
Keywords: ABBV, AI, AI inference, AMD, AMN, BMO, BMY, CIQ, CME, DVA, GPU, Google Cloud, HPC, Instinct GPUs, Meta, NVAX, OpenAI, ROCm, Rocky Linux, Stocktwits, analyst targets, branded drugs, chip industry, chipmaker, data center, derivatives, digital settlement, drug imports, drug tariffs, financial markets, healthcare policy, healthcare sector, investment narrative, margins, market reaction, pharmaceutical, policy risk, stock decline, stock surge, tokenized cash, trading volumes, valuation